Teriparatide (PTH 1-34) 10mg

Disclaimer: All Iron Mountain Labz products are only intended for laboratory research use and are not approved for human consumption.

Overview of Teriparatide (PTH 1-34) 10mg

Teriparatide is a synthetic 34-amino-acid peptide corresponding to the N-terminal fragment of parathyroid hormone (PTH). It is classified as a parathyroid hormone receptor 1 (PTH1R) agonist. It is supplied by Iron Mountain Labz as a research-grade lyophilized peptide in vials. In preclinical bone remodeling research, it has been investigated for its interactions with PTH1R, a G protein-coupled receptor expressed in

• Osteoblasts,
• Renal tubular cells, and
• Various other tissue types in animal models

A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications under medical supervision. The research-grade preparation supplied here is a distinct laboratory compound. It is a 10mg lyophilized peptide vial produced for preclinical and in vitro research use only. It is not a pharmaceutical product, not a clinical preparation, and is not supplied for any human application. It is not a dietary supplement.

Teriparatide vials are available at Iron Mountain Labz for the following research applications:

• In vitro PTH1R receptor binding investigation
• Preclinical bone remodeling pathway research
• Osteoblast biology laboratory studies

Chemical Properties

Section	Details
CAS Number	52232-67-4
Molar Mass	4,117.72 g/mol
Chemical Formula	C₁₈₁H₂₉₁N₅₅O₅₁S₂
PubChem CID	16133850
IUPAC Name	H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
Synonyms	PTH 1-34, Parathyroid Hormone Fragment 1-34, hPTH(1-34)
Format	10mg Lyophilized Vial
Ingredients / Composition	Teriparatide (PTH 1-34), ≥98% purity (HPLC verified)
Physical Form	White to off-white lyophilized powder
Solubility	Soluble in sterile water or acetic acid solution; limited solubility in organic solvents
Shelf Life	Up to 24 months when stored under recommended conditions in lyophilized form
Storage Instructions	Store at −20°C, protected from light and moisture. Avoid repeated freeze-thaw cycles. Use within one month once opened.
Disclaimer	A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications. This research-grade vial preparation is a distinct laboratory compound not approved for human or veterinary use.
Classification	Research Use Only (RUO)

Formulation note: The acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol) is also available from some suppliers. The values above reflect the free peptide entry for CAS 52232-67-4. Researchers should confirm the specific form of the material in use, as the two variants differ in molecular weight and may affect experimental design.

Teriparatide (PTH 1-34)’ Mechanism of Action in Research Models

PTH1R Receptor Binding and cAMP Signaling Research:

Teriparatide has been investigated in preclinical cell and tissue models as a PTH1R agonist. In isolated receptor preparations and cell culture systems, PTH1R binding by teriparatide has been observed to activate adenylate cyclase, increasing intracellular cAMP levels and activating downstream protein kinase A signaling cascades. This receptor-mediated second messenger pathway is the primary mechanism under investigation in PTH1R pharmacology research.

Osteoblast Activation and Bone Formation Pathway Research:

In rodent preclinical models and isolated osteoblast cell systems, intermittent PTH1R activation by teriparatide has been associated with modulation of osteoblast differentiation, proliferation, and apoptosis pathways.

Research in this area has investigated how PTH1R signaling may shift the balance between bone-forming and bone-resorbing cellular activity in experimental model systems.

RANKL/OPG Pathway Modulation Research:

In animal model studies, teriparatide has been investigated for its potential to modulate RANKL (receptor activator of nuclear factor kappa-B ligand) and osteoprotegerin (OPG) signaling. The interaction between PTH1R activation and the RANKL/OPG axis in bone remodeling model systems remains an active area of preclinical investigation.

Bone Remodeling Marker Research:

In preclinical bone remodeling model systems, teriparatide administration has been observed to modulate serum markers of bone formation and resorption, including osteocalcin and CTX-1, in a dose and frequency-dependent manner. This has made it a reference compound in preclinical studies investigating bone remodeling dynamics.

Risk & Handling

Teriparatide is a synthetic polypeptide PTH1R agonist under investigation in preclinical bone remodeling research.

Risk tier: HIGH.

This rating reflects teriparatide’s potent endocrine activity on calcium homeostasis pathways, the bioactive concentrations used in preclinical research, and the need for strict handling protocols to prevent accidental exposure during reconstitution.

Researchers must observe:

Handling Precautions: Teriparatide should be handled exclusively in a controlled laboratory environment by trained personnel. Avoid skin and eye contact during reconstitution and handling. Use appropriate PPE at all times.

Exposure Risks: Teriparatide is a PTH1R agonist research peptide that is thought to modulate calcium homeostasis, cAMP signaling, and bone remodeling pathways in preclinical models. No human safety data has been established for the research-grade formulation supplied here.

Storage: Store lyophilized teriparatide at −20°C in a dry, dark environment. Protect from light, heat, and moisture at all times. Avoid repeated freeze-thaw cycles.

Why Buy Teriparatide (PTH 1-34) from Iron Mountain Labz?

Researchers prefer Iron Mountain Labz to buy Teriparatide (PTH 1-34) due to the following reasons.

• Purity of Teriparatide (PTH 1-34) verified at ≥98% (by HPLC per product specification)
• Physical form confirmed as white to off-white lyophilized powder
• Supplied as a 10mg lyophilized vial (fit for preclinical and in vitro laboratory use)
• Formulation note included with each batch

Note: The Peptide Single Vials category at Iron Mountain Labz also includes other PTH-related and bone biology research compounds. These peptides are studied for their effects on receptor signaling and bone remodeling pathways in preclinical research models.

For queries, complaints, or support, please contact help@ironmountainlabz.com

Frequently Asked Questions

Is Teriparatide (PTH 1-34) legal in the United States?

The research-grade vial preparation supplied here is a distinct laboratory compound. It is not approved for other conditions and is available for research purposes only in the United States.

What is Teriparatide (PTH 1-34) used for in research models?

In controlled laboratory environments, teriparatide vials have been investigated for:

• PTH1R receptor binding kinetics and structure-activity relationship studies,
• Osteoblast differentiation and apoptosis pathway investigation
• RANKL/OPG signaling axis research,
• Comparative PTH fragment pharmacology studies against full-length PTH(1-84) analogs, and
• Bone remodeling marker modulation studies in rodent preclinical models

How should Teriparatide (PTH 1-34) be stored?

Store vials at −20°C in a dry, dark environment, protected from light, heat, and moisture. Avoid repeated freeze-thaw cycles, as these may degrade peptide integrity and reduce receptor-binding activity.

What formulation variants of teriparatide exist for research purposes?

Teriparatide is commercially available in both free peptide form (CAS 52232-67-4, MW 4,117.72 g/mol) and acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol). Researchers should confirm the specific form of the material in use, as the two variants differ in molecular weight and may affect experimental design. Iron Mountain Labz supplies the free peptide form.

References

Jilka, R. L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434–1446. PMID: 17517365. https://pubmed.ncbi.nlm.nih.gov/17517365/

Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation. 1999;104(4):439–446. PMID: 10449436. https://pubmed.ncbi.nlm.nih.gov/10449436/